|Publication number||US4746667 A|
|Application number||US 06/939,274|
|Publication date||24 May 1988|
|Filing date||10 Dec 1986|
|Priority date||13 Aug 1981|
|Also published as||CA1226223A, CA1226223A1, DE3270116D1, EP0074341A1, EP0074341B1|
|Publication number||06939274, 939274, US 4746667 A, US 4746667A, US-A-4746667, US4746667 A, US4746667A|
|Inventors||Enar I. Carlsson, Hakan S. Larsson, Gunhild W. von Wittken Sundell, Viola I. Samuelsson-Junggren, Kenneth Lundstrom|
|Original Assignee||Aktiebolaget Hassle|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (11), Non-Patent Citations (3), Referenced by (12), Classifications (9), Legal Events (7)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation-in-part of application Ser. No. 804,328, filed on Dec. 4, 1985 now abandoned which is a continuation of application Ser. No. 620,527, filed on 6/12/84, now abandoned, which is a continuation of application Ser. No. 400,388, filed on July 21, 1982 now abandoned.
1. Field of the Invention
The object of the present invention is to provide compounds which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the treatment of peptic ulcer.
The present invention relates to the use of a group of benzimidazole derivatives, or therapeutically acceptable salts thereof, for inhibiting gastric acid secretion in mammals and man. In a more general sense, the invention relates to the use of the compounds for treatment of gastrointestinal inflammatory diseases in mammals and man, including i.e. gastric and duodenal ulcer. Furthermore it relates to the use of these compounds for treatment of other gastrointestinal disorders, where a gastric antisecretory effect is desirable i.e. in patients with gastrinomas and in patients with acute upper gastrointestinal bleeding. The invention also relates to pharmaceutical compositions containing at least one member of the said group of benzimidazole derivatives, or a therapeutically acceptable salt thereof, as active ingredient. In a further aspect, the invention relates to new compounds, and therapeutically acceptable salts thereof, within the said group of benzimidazole derivatives, and to processes for preparation of such new compounds.
2. Prior Art
Benzimidazole derivatives intended for inhibiting gastric acid secretion are disclosed in the British patent specification Nos. 1 500 043 and 1 525 958, in the U.S. Pat. No. 4,182,766 and in the European patent specification No. 0 005 129.
It has been found that the compounds of the formula ##STR2## and therapeutically acceptable salts thereof in which formula
R1 and R2 are the same or different and each selected from the group consisting of H, CF3, NO2, --COOCH3, --COOC2 H5, alkyl containing 1-7 carbon atoms, halogen, alkoxy containing 1-5 carbon atoms, and alkanoyl containing 1-4 carbon atoms;
R is selected from the group consisting of H, alkanoyl containing 1-4 carbon atoms, and carboalkoxy containing 2-6 carbon atoms; and
R3, R4 and R5, which are the same or different, are each selected from the group consisting of H, CH3, C2 H5, OCH3, OC2 H5, OCH2 CH2 OCH3, and OCH2 CH2 OCH2 CH3, provided that
(a) at least one of R3, R4 and R5 is selected from the group consisting of CH3, C2 H5, OCH3, OC2 H5, OCH2 CH2 OCH3, and OCH2 CH2 OCH2 CH3, and
(b) when two of R3, R4 and R5 are H, then the remaining radical R3, R4 or R5 is selected from the group consisting of OCH3, OC2 H5, OCH2 CH2 OCH3, and OCH2 CH2 OCH2 CH3 ;
are effective as inhibitors of gastric acid secretion in mammals and man. The compounds of the formula I, and therapeutically acceptable salts thereof, are stable in gastric juice, which is of importance at oral administration.
Illustrative examples of the radicals in the formula I are:
Alkyl groups R1 and R2 : methyl, ethyl, n-propyl, i-propyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, n-hexyl, n-heptyl. It is preferred that alkyl groups R1 and R2 contains 1, 2, 3 or 4 carbon atoms. The preferred alkyl group is methyl.
Halogen R1 and R2 : chloro, bromo, fluoro, iodo. The preferred halogen groups are chloro and bromo.
Alkoxy groups R1 and R2 : methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, sec.-butoxy, isobutoxy, tert.-butoxy, n-pentoxy. It is preferred that alkoxy groups R1 and R2 contain 1, 2 or 3 carbon atoms. The preferred alkoxy group is methoxy.
Alkanoyl groups R, R1 and R2 : HCO--, CH3 CO--, CH3 CH2 CO--, CH3 CH2 CH2 CO--, ##STR3## The preferred alkanoyl group R1 and R2 is CH3 CO. The preferred alkanoyl group R is CH3 CO.
Carboalkoxy groups R: ##STR4## It is preferred that carboalkoxy groups R contains 2 or 3 carbon atoms. Thus, the groups CH3 OCO-- and CH3 CH2 OCO-- are preferred.
The preferred meaning of the radical R is H.
Preferred combinations of the radicals in the formula I, subject to the two provisos (a) and (b) given above, are given in Table 1 below.
TABLE 1______________________________________Preferred combinations of R.sup.1, R.sup.2, R, R.sup.3, R.sup.4 andR.sup.5R.sup.1 and R.sup.2, R.sup.3, R.sup.4 and R.sup.5,the same or different if the same or different ifnot indicated otherwise R not indicated otherwise______________________________________H, COOCH.sub.3, COOC.sub.2 H.sub.5 H H, CH.sub.3, C.sub.2 H.sub.5, OCH.sub.3alkyl, halogen, alkoxy, OC.sub.2 H.sub.5, OCH.sub.2 CH.sub.2 OCH.sub.3,alkanoyl OCH.sub.2 CH.sub.2 OCH.sub.2 CH.sub.3H, COOCH.sub.3, CH.sub.3, Cl, Br, H H, CH.sub.3, C.sub.2 H.sub.5, OCH.sub.3,OCH.sub.3, CH.sub.3 CO OCH.sub.2 CH.sub.2 OCH.sub.3H, COOCH.sub.3, CH.sub.3, OCH.sub.3, H CH.sub.3, OCH.sub.3CH.sub.3 COH, COOCH.sub.3, alkyl H H, CH.sub.3, OCH.sub.3, OC.sub.2 H.sub.5alkoxy, alkanoylH, COOCH.sub.3, COOC.sub.2 H.sub.5, H R.sup.3 : CH.sub. 3alkyl, halogen, alkoxy, R.sup.4 : OCH.sub.3alkanoyl R.sup.5 : CH.sub.3H, COOCH.sub.3, COOC.sub.2 H.sub.5, H R.sup.3 : Halkyl, alkoxy, R.sup.4 : OCH.sub.3alkanoyl R.sup.5 : CH.sub.3NO.sub.2, CF.sub.3 H R.sup.3 : CH.sub.3 R.sup.4 : OCH.sub.3 R.sup.5 : CH.sub.3H, COOCH.sub.3, COOC.sub.2 H.sub.5, H R.sup.3 : CH.sub.3alkyl, alkoxy, R.sup.4 : OCH.sub.3alkanoyl R.sup.5 : HH, COOCH.sub.3, COOC.sub.2 H.sub.5, H R.sup.3 : Halkyl, alkoxy, R.sup.4 : OCH.sub.3alkanoyl R.sup.5 : HH, COOCH.sub.3, COOC.sub.2 H.sub.5, H R.sup.3 : CH.sub.3alkyl, alkoxy, R.sup.4 : Halkanoyl R.sup.5 : CH.sub.3H, COOCH.sub.3, COOC.sub.2 H.sub.5, H R.sup.3 : Halkyl, alkoxy, R.sup.4 : OCH.sub.3, OC.sub.2 H.sub.5,alkanoyl OCH.sub.2 CH.sub.2 OCH.sub.3, OCH.sub.2 CH.sub.2 OCH.sub.2 CH.sub.3 R.sup.5 : HH, COOCH.sub.3, COOC.sub.2 H.sub.5, H R.sup.3 : CH.sub.3alkyl, alkoxy R.sup.4 : CH.sub.3alkanyol R.sup.5 : CH.sub.3______________________________________
The radicals R1 and R2 can be bound to the benzimidazole nucleus in any of the positions 4, 5, 6 and 7 as depicted in formula I. It is preferred that R1 and R2 are in position 5 and/or 6.
Preferred individual compounds among those included in the formula I are given in the following Table 2:
TABLE 2______________________________________Preferred individual compoundsR.sup.1 R.sup.2 R R.sup.3 4.sup.4 R.sup.5______________________________________5-OCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.35-COOCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.35-COOCH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 CH.sub.35-COCH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 CH.sub.35-COCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.35-CH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.35-COCH.sub.3 6-CH.sub.3 H H CH.sub.3 CH.sub.35-OCH.sub.3 H H CH.sub.3 CH.sub.3 CH.sub.35-COCH.sub.3 6-CH.sub.3 H H OCH.sub.3 H5-COOCH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 H5-COCH.sub.3 6-CH.sub.3 H CH.sub.3 CH.sub.3 CH.sub.35-COOCH.sub.3 6-CH.sub.3 H H OCH.sub.3 H______________________________________
Further preferred individual compounds are those exemplified in the examples given elsewhere in this specification.
In the prior art cited above, no medicinal use is disclosed for the compounds of the formula I. Thus, the present invention comprises pharmaceutical compositions containing a comppound of the formula I or a therapeutically acceptable salt thereof as active ingredient, and the use of the compounds of the formula I or a therapeutically acceptable salt thereof for inhibiting gastric acid secretion in mammals and man.
The compounds of the formula I wherein R1 and R2 are as defined above except CF3 and NO2, R is H and R3, R4 and R5 are H, CH3, OCH3, OC2 H5, OCH2 CH2 OCH3 or OCH2 CH2 OCH2 CH3 are generically disclosed as chemical intermediates in the European patent No. 0 005 129. The specific compounds disclosed in the following Table 3 are disclosed in the said European Pat. No. 0 005 129.
TABLE 3______________________________________Compounds disclosed in European patent no. 0 005 129.R R.sup.1 R.sup.2 R.sup.3 R.sup.4 R.sup.5 Remark______________________________________H 5-COCH.sub.3 6-CH.sub.3 H CH.sub.3 CH.sub.3 baseH 4-CH.sub.3 6-CH.sub.3 CH.sub.3 H CH.sub.3 hydrochlorideH 5-COCH.sub.3 6-CH.sub.3 CH.sub.3 CH.sub.3 CH.sub.3 base______________________________________
The present invention, in so far as it concerns compounds of the formula I by themselves, their pharmaceutically acceptable salts, and processes for their preparations, relates to
(i) the compounds of the formula I wherein R3, R4 or R5 is C2 H5
(ii) the compounds of the formula I wherein R is alkanoyl or carboalkoxy
(iii) the compounds of the formula I wherein R is H except the compounds wherein R, R1, R2, R3, R4 and R5 are combined as follows:
______________________________________R.sup.1 R.sup.2 R R.sup.3 R.sup.4 R.sup.5______________________________________5-COCH.sub.3 6-CH.sub.3 H H CH.sub.3 CH.sub.34-CH.sub.3 6-CH.sub.3 H CH.sub.3 H CH.sub.35-COCH.sub.3 6-CH.sub.3 H CH.sub.3 CH.sub.3 CH.sub.3______________________________________
(iv) the compounds of the formula I wherein R1 and/or R2 are CF3 or NO2.
The preferred compounds within the groups (i), (ii), (iii) and (iv) will comprise the same compounds that are indicated as preferred in Table 1 and Table 2 above, subject to the proviso that the specific compounds listed in Table 3 are excluded.
The compounds of the formula I can be prepared by known methods such as
A. reacting a compound of the formula ##STR5## with a compound of the formula ##STR6## in which formulas R, R1, R2, R3, R4 and R5 are as defined previosly and wherein one of Z1 and Z2 is SH and the other is a leaving group.
Examples of leaving groups Z1 and Z2 in the compounds II and III are halogens, preferably chlorine, bromine or iodine, acyl radicals, for example, residues of strong organic sulfonic acids, for instance, of an arylsulfonic acid, for example, tosyloxy, or an alkylsulfonic acid, for example, mesyloxy; alkylmercapto groups, for example, methylmercapto; alkylsulfinyl groups, for example, methylsulfinyl and the like.
Thus, Z1 or Z2 when designating leaving groups may be a reactive esterified hydroxy group.
The reaction of a compound of formula II above with a compound of formula III is conveniently carried out in the presence of a suitable solvent that is inert under the reaction conditions utilized as described hereinafter. The reaction may further be carried out in the presence of a suitable base. Suitable bases include, for example, inorganic bases such as sodium or potassium hydroxide, sodium or potassium hydride and the like, organic bases such as tertiary amines, for example, triethylamine and the like.
Suitable solvents for the above described reaction include, for example, alcohols, preferably lower alkanols such as, methanol and ethanol; mixtures of such alcohols with water, ethers, such as, tetrahydrofuran; halogenated hydrocarbons, such as, methylene chloride and chloroform, and the like.
The reaction of the compounds of formulas II and III may be carried out at a temperature between the ambient temperature and the boiling temperature of the reaction mixture. It is preferred to carry out the reaction, however, at a temperature at or close to the boiling point of the reaction mixture for the preparation of a compound of the formula I wherein R is H;
B. reacting a compound of the formula ##STR7## wherein R1 and R2 have the same meaning as given above with a compound of the formula ##STR8## wherein R3, R4 and R5 have the same meaning as given above, to the formation of a compound of the formula I wherein R is H;
C. reacting a compound of the formula ##STR9## wherein R, R1 and R2 have the meaning given above and M is K, Na or Li, with a compound of formula ##STR10## wherein R3, R4 and R5 have the meaning given above and Z3 is a reactive esterified hydroxy group, to the formation of a compound of the formula I.
The reactive esterified hydroxy group Z3 may, as in the case of Z1 and Z2, be a hydroxy group esterified with a strong, inorganic or organic acid, preferably a hydrohalogen acid, such as hydrochloric acid, hydrobromic acid, or hydroiodic acid, or esterified with sulfuric acid or with a strong organic sulfonic acid such as a strong aromatic acid, e.g. benzenesulfonic acid, 4-bromobenzenesulfonic acid or 4-toluenesulfonic acid.
D. reduction of a compound of the formula ##STR11## to the formation of a compound of the formula I:
E. for the preparation of a compound of the formula I wherein the radicals R1 and/or R2 is COOCH3 or COOC2 H5, reacting a compound of the formula ##STR12## wherein R, R3, R4 or R5 are as defined above and wherein Y1 is --COOH, or a functionally equivalent derivative thereof, and Y2 is --COOH, or a functionally equivalent derivative thereof, or R1, with
CH.sub.3 OH X
CH.sub.3 CH.sub.2 OH XI
or a functionally equivalent derivative thereof, to the formation of a compound of the formula I wherein R1 and/or R2 is CH3 COO or CH3 CH2 COO.
This reaction is an ordinary esterification which is carried out in customary manner.
Functionally equivalent derivatives of the hydroxy group in the compounds X and XI are for example halogen such as Cl or Br, or --N2.
Functionally equivalent derivatives of the carboxyl group Y1 and Y2 are for example a metal carboxylate group or an activated carboxyl group, in which case the radicals Y1 or Y2 are for example an acid chloride, an alkyl ester, an acid anhydride or a mixed anhydride with formic esters or carboxylic acids, sulphonic or inorganic esters or derivatives obtained by a reaction between a carboxylic acid and a carbodiimide or similarly functioning compounds such as N1 N1 -carbonyldiimidazole or N-ethyl-5-phenylisoxazolium-31 -sulphonate, the derivative of the carboxyl group Y1 or Y2 being a metal carboxylate group when the hydroxyl group in the compounds X or XI is replaced with halogen. A further functionally equivalent derivative of the carboxyl groups Y1 and Y2 is the group --CN, in which case a cyanide is reacted with a compound of the formula X or XI with subsequent hydrolysis to give a compound of the formula I wherein R1 and/or R2 is CH3 COO or CH3 CH2 COO.
F. for the preparation of a compound of the formula I wherein at least one of R3, R4 and R5 is OCH3, OC2 H5, OCH2 CH2 OCH3 or OCH2 CH2 OCH2 CH3, reacting a compound of the formula ##STR13## wherein R, R1 and R2, are as defined above and Z3, Z4 and Z5 represent either R3, R4 and R5, respektively, or halogen such as Cl, Br, F or I, or NO2, whereby at least one of Z3, Z4 and Z5 represents halogen or NO2, with a compound of the formula
R.sup.6 --O--M XIII
wherein R6 is CH3, C2 H5, CH2 CH2 OCH3 or CH2 CH2 OCH2 CH3, and M is Na, K, or Li, to the formation of a compound of the formula I wherein at least one of R3, R4 and R5 is OCH3, OC2 H5, OCH2 CH2 OCH3 or OCH2 CH2 OCH2 CH3 ;
G. for the preparation of a compound of the formula I wherein at least one of R3, R4 and R5 is OCH2 CH2 OCH3 or OCH2 CH2 OCH2 CH3, reacting a compound of the formula ##STR14## wherein R, R1 and R2 are as defined above, and Z6, Z7 and Z8 represent either R3, R4 and R5, respektively, or a radical
OCH.sub.2 CH.sub.2 Y XV
where Y is halogen, whereby at least one of Z6, Z7 and Z8 represent OCH2 CH2 Y, with a compound of the formula
R.sup.7 --O--M XVI
wherein R7 is CH3 or CH2 CH3 and M is Na, K or Li, to the formation of a compound of the formula I wherein at least one of R3, R4 and R5 is OCH2 CH2 OCH3 or OCH2 CH2 OCH2 CH3.
Method F and Method G represent the known Williamson ether synthesis and is carried out in known manner.
H. for the preparation of a compound of the formula I wherein R is H, hydrolyzing a compound of the formula ##STR15## wherein R1, R2, R3, R4 and R5 are as defined above and Z9 is an alkanoyl group or a carboalkoxy group, to the formation of a compound of the formula I wherein R is H.
The radical Z9 can be an alkanoyl group containing 1-6 carbon atoms or a carboalkoxy group containing 2-6 carbon atoms.
I. reduction of a compound of the formula ##STR16## to the formation of a compound of the formula I.
J. reduktion of a compound of the formula ##STR17## to the formation of a compound of the formula I.
Depending on the process conditions and the starting materials, the end product of the formula I is obtained either as the free base or as a salt. Both the free base and the salts of the end products are included within the scope of the invention. Thus, basic, neutral or mixed salts may be obtained as well as hemi, mono, sesqui or polyhydrates. Acid addition salts of the new compounds may in a manner known per se be transformed into free base using basic agents such as alkali or by ion exchange. The free bases obtained may also form salts with organic or inorganic acids. In the preparation of acid addition salts preferably such acids are used which form suitable therapeutically acceptable salts. Examples of such acids are hydrohalogen acids, sulfonic acid, phosphoric acid, nitric acid, and perchloric acid; aliphatic, alicyclic, aromatic or heterocyclic carboxyl or sulfonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, salicylic acid or p-aminosalicylic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, halogenbenzenesulfonic acid, toluenesulfonic acid, naphtylsulfonic acid or sulfanilic acids; methionine, tryptophane, lysine or arginine.
These or other salts of the new compounds, as e.g. picrates, may serve as purifying agents of the free bases obtained. Salts of the bases may be formed, separated from solution, and then the free base can be recovered in higher purity from a new salt solution.
The starting materials utilized in the processes A-J are known or may, if they should be new, be obtained according to processes known per se.
In clinical use the active compounds of the formula I will normally be administered orally, rectally or by injection in the form of a pharmaceutical preparation which contains the active component either in the form of the free base or in the form of a pharmaceutically acceptable, non-toxic salt, as described earlier, optionally in combination with a pharmaceutically acceptable carrier. The carrier may be in the form of a solid, semisolid or liquid diluent, or a capsule. These pharmaceutical preparations are a further object of the invention. The compounds may also be used without carrier material. Usually the amount of active compound is between 0.1 and 99% by weight of the preparation, for example between 0.5 to 20% by weight in preparations for injection and between 2 and 50% by weight in preparations for oral administration.
In the preparation of pharmaceutical preparations containing a compound of the formula I in the form of dosage units for oral administration, the active compound may be mixed with a solid, pulverulent carrier, such as lactose, saccharose, sobitol, mannitol, a starch such as potatoe starch, corn starch, or amylopectin, cellulose derivatives or gelatin, and may also include a lubricant such as magnesium stearate, calcium stearate or polyethyleneglycol waxes. The mixture is then pressed into tablets. If coated tablets are desired, a core prepared as described above may be coated with a concentrated sugar solution which may contain gum arabic, gelatin, talc, tatanium dioxide or alternatively with a lacquer dissolved in volatile organic solvents or mixtures of solvents. To this coating various dyes may be added in order to distinguish tablets with different active compounds or with different amounts of the active compound present.
Soft gelatin capsules may be prepared which capsules contain a mixture of the active compound or compounds and vegetable oil. Hard gelatin capsules may contain granules of the active compound in combination with a solid, pulverulent carrier as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.
Dosage units for rectal administration may be prepared in the form of suppositories which contain the active substance in admixture with a neutral fatty base, or they may be prepared in the form of gelatin-rectal capsules which contain the active substance in admixture with a vegetable oil or with paraffin oil.
Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions containing from 0.2% to 20% by weight of the active ingredient, the remainder comprising for example sugar and a mixture of ethanol, water, glycerol and propylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharin and carboxymethylcellulose as a thickening agent.
Solutions for parenteral administration by injection may be prepared as sterile solution, for example in pyrogen-free water, of a water soluble pharmaceutically acceptable salt of the active compound, preferably in a concentration from 0.5% to 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may be manufactured in different dosage unit ampoules.
The dosage at which the active substance are administered may vary within a wide range and will depend on various factors such as for example the individual requirements of each patient and the manner of administration. In general, oral dosages will be in the range from 100 to 400 mg/day of active substance and intravenous dosages in a range from 5 to 20 mg/day.
The invention is illustrated by the following examples.
22.2 g (0.1 mole) of 3,5-dimethyl-4-methoxy-2-chloromethylpyridine hydrochloride and 20.6 g (0.1 mole) of 5-COCH3 -6-CH3 -2-mercapto benzimidazole was dissolved in 250 ml methanol whereafter 4 g (0.1 mole) NaOH dissolved in 25 ml H2 O was added. The mixture was heated to reflux and an additional amount of 4 g (0.1 mole) NaOH in 25 ml H2 O was added dropwise during 15 min. The mixture was thereafter refluxed during 6 hours whereafter it was cooled and diluted with 500 ml H2 O. The resulting mixture was extracted with CH2 Cl2, dried and evaporated. The remainder was recrystallized from acetonitrile giving the title substance in the form of free base. Yield: 30 g (85% of the theoretical yield). M.P.: 139° C.
The compounds indentified by example numbers 2-50 in the following Table 4 were prepared using the same method of preparation as in Example 1. The compounds were obtained in the form of their free base. The compound of Example 1 is also included in the table.
TABLE 4__________________________________________________________________________Identifying data for compounds of the invention ##STR18##Exampleno R.sup.1 R.sup.2 R R.sup.3 R.sup.4 R.sup.5 M.p. °C.__________________________________________________________________________1 5-COCH.sub.3 6-CH.sub.3 H H CH.sub.3 CH.sub.3 1482 5-COOCH.sub.3 6-CH.sub.3 H H CH.sub.3 CH.sub.3 1253 5-COOCH.sub.3 H H H CH.sub.3 CH.sub.3 1364 5-COCH.sub.3 6-CH.sub.3 H CH.sub.3 CH.sub.3 H 1405 5-COOCH.sub.3 6-CH.sub.3 H CH.sub.3 CH.sub.3 H 170 (oil)6 4-CH.sub.3 6-CH.sub.3 H CH.sub.3 H CH.sub.3 2067 5-COCH.sub.3 6-CH.sub.3 H CH.sub.3 H CH.sub.3 1258 5-COCH.sub.3 6-CH.sub.3 H CH.sub.3 CH.sub.3 CH.sub.3 100 (oil)9 5-COCH.sub.3 6-CH.sub.3 H H OCH.sub.3 H 9710 4-CH.sub.3 6-CH.sub.3 H H OCH.sub.3 H 11011 5-COCH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 CH.sub.3 13912 5-COOCH.sub.3 6-CH.sub.3 H CH.sub.3 H CH.sub.3 13013 5-COOCH.sub.3 6-CH.sub.3 H CH.sub.3 CH.sub.3 CH.sub.3 18414 5-COOCH.sub.3 6-CH.sub.3 H H OCH.sub.3 H 14615 5-COOCH.sub.3 6-CH.sub.3 H H OC.sub.2 H.sub.5 H 90-9416 5-COOCH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 H 16017 5-COOCH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 CH.sub.3 11918 5-COOCH.sub.3 6-CH.sub.3 H H OCH.sub.3 CH.sub.3 18419 5-COOCH.sub.3 H H CH.sub.3 H CH.sub.3 13020 5-COOCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.3 17521 5-COCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.3 122-12422 5-OCH.sub.3 H H H OCH.sub.3 CH.sub.3 16823 5-OCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.3 110-11924 5-CH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub. 3 14825 H H H CH.sub.3 OCH.sub.3 CH.sub.3 12526 5-Cl H H CH.sub.3 OCH.sub.3 CH.sub.3 18027 5-CH.sub.3 H H H OC.sub.2 H.sub.4 OCH.sub.3 H 10028 5-COOC.sub.2 H.sub.5 H H CH.sub.3 OCH.sub.3 CH.sub.3 13029 5-OCH.sub.3 H H CH.sub.3 CH.sub.3 CH.sub.3 15730 CH.sub.3 CH.sub.3 H CH.sub.3 CH.sub.3 H 14031 COOCH.sub.3 CH.sub.3 H CH.sub.3 H CH.sub.3 12532 5-C(CH.sub.3).sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.333 5-NO.sub.2 H H CH.sub.3 OCH.sub.3 CH.sub.334 5-CH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 CH.sub.335 4-CH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 CH.sub.336 5-C.sub.2 H.sub.5 H H CH.sub.3 OCH.sub.3 CH.sub.337 5-CF.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.338 5-CH(CH.sub.3).sub.2 H H CH.sub.3 OCH.sub.3 CH.sub.339 5-Cl 6-Cl H CH.sub.3 OCH.sub.3 CH.sub.340 5-OC.sub.2 H.sub.5 H H CH.sub.3 OCH.sub.3 CH.sub.341 5-Br H H CH.sub.3 OCH.sub.3 CH.sub.342 5-OCH.sub.3 H H OCH.sub.3 H H43 5-Cl H H CH.sub.3 CH.sub.3 H44 5-OCH.sub.3 H H CH.sub.3 CH.sub.3 H45 5-CH.sub.3 7-CH.sub.3 H CH.sub.3 CH.sub.3 H46 5-OCH.sub.3 H H CH.sub.3 OCH.sub.3 H47 5-COOCH.sub.3 7-CH.sub.3 H CH.sub.3 CH.sub.3 H48 5-COCH.sub.3 H H CH.sub.3 CH.sub.3 H49 5-OCH.sub.3 H H CH.sub.3 OC.sub.2 H.sub.5 CH.sub.350 5-COOCH.sub.3 6-CH.sub.3 H H OCH.sub.3 C.sub.2 H.sub.5__________________________________________________________________________
Identifying data for the compounds according to examples 32-50 are given in the following Table 5.
TABLE 5______________________________________NMR data for compounds of the inventionCompound according NMR datato example no. δ______________________________________32 1.37 (s,9H), 2.26 (s,3H), 2.30 (s,3H), 3.76 (s,3H), 4.37 (s,2H), 7.25 (k,1H), 7.49 (d,1H), 7.57 (d,1H), 8.30 (s,1H)33 2.21 (s,3H), 2.31 (s,3H), 3.75 (s,3H), 4.77 (s,2H), 7.64 (d,1H), 8.11 (k,1H), 8.23 (s,1H), 8.36 (d,1H)34 2.23 (s,3H), 2.28 (s,3H), 2.33 (s,6H), 3.75 (s,3H), 4.33 (s,2H), 7.29 (s,2H), 8.23 (s,1H)35 2.28 (s,3H), 2.33 (s,3H), 2.43 (s,3H), 2.58 (s,3H), 3.81 (s,3H), 4.42 (s,2H), 6.92 (s,1H), 7.29 (s,1H), 8.36 (s,1H)36 1.25 (t,3H), 2.25 (s,3H), 2.30 (s,3H), 2.72 (k,2H), 3.76 (s,3H), 4.38 (s,2H), 7.02 (k,1H), 7.35 (d,1H), 7.45 (d,1H), 8.26 (s,1H)37 2.31 (s,3H), 2.35 (s,3H), 3.84 (s,3H), 4.46 (s,2H), 7.51 (k,1H), 7.70 (d,1H), 7.92 (d,1H), 8.38 (s,1H)38 1.25 (s,3H), 1.33 (s,3H), 2.27 (s,3H), 2.33 (s,3H), 3.03 (m,1H), 3.80 (s,3H), 4.51 (s,2H), 7.17 (k,1H), 7.53 (d,1H), 7.58 (d,1H), 8.36 (s,1H)39 2.22 (s,3H), 2.31 (s,3H), 3.81 (s,3H), 4.72 (s,2H), 7.76 (s,2H), 8.23 (s,1H)40 1.41 (t,3H), 2.30 (s,3H), 2.35 (s,3H), 3.82 (s,3H), 4.10 (k,2H), 4.39 (s,2H), 6.92 (k,1H), 7.14 (d,1H), 7.52 (d,1H), 8.40 (s,1H)41 2.16 (s,3H), 2.26 (s,3H), 3.71 (s,3H), 4.68 (s,2H), 7.23 (k,1H), 7.43 (d,1H), 7.65 (d,1H), 8.18 (s,1H)42 3.80 (s,3H), 3.83 (s,3H), 4.50 (s,2H), 6.90 (k,1H), 7.15 (d,1H), 7.24 (m,2H), 7.53 (d,1H), 8.23 (k,1H)43 2.33 (s,3H), 2.35 (s,3H), 4.80 (s,2H), 7.19 (m,2H), 7.52 (d,1H), 7.58 (d,1H), 8.34 (d,1H)44 2.34 (s,6H), 3.85 (s,3H), 4.51 (s,2H), 6.89 (k,1H), 7.15 (d,1H), 7.15 (d,1H), 7.53 (d,1H), 8.41 (d,1H)45 2.16 (s,6H), 2.38 (s,3H), 2.53 (s,3H), 4.46 (s,2H), 6.86 (s,1H), 6.99 (d,1H), 7.25 (s,1H), 8.20 (d,1H)46 2.26 (s,3H), 3.86 (s,3H), 3.91 (s,3H), 4.70 (s,2H), 6.87 (m,2H), 7.10 (d,1H), 7.48 (d,1H), 8.42 (d,1H)47 2.36 (s,6H), 2.65 (s,3H), 3.97 (s,3H), 4.50 (s,2H), 7.17 (d,1H), 7.84 (s,1H), 8.24 (s,1H), 8.41 (d,1H),48 2.31 (s,3H), 2.34 (s,3H), 2.64 (s,3H), 4.71 (s,2H), 7.12 (d,1H), 7.59 (d,1H), 7.91 (k,1H), 8.22 (d,1H), 8.36 (d,1H)49 1.41 (t,3H), 2.27 (s,3H), 2.31 (s,3H), 3.87 (s,3H), 3.94 (k,2H), 4.41 (s,2H), 6.89 (k,1H), 7.12 (d,1H), 7.50 (d,1H), 8.35 (s,1H)50 1.17 (t,3H), 2.61 (k,2H), 2.69 (s,3H), 3.93 (s,6H), 4.43 (s,2H), 7.00 (s,1H), 7.45 (s,1H), 8.26 (s,1H), 8.35 (s,1H)______________________________________
The starting materials in the Examples 1-50 were prepared in accordance with the following:
(1) a substituted o-phenylenediamine was reacted with potassium etylxanthate (according to Org. Synth. Vol. 30, p. 56) to form a corresponding substituted 2-mercaptobenzimidazole;
(2) a substituted 2-chloromethylpyridine was prepared by reacting the corresponding 2-hydroxymethylpridine with thionylchloride;
(3) a substituted 2-chloromethylbenzimidazole was prepared by condensing the o-phenylenediamine with chloroacetic acid.
The following examples illustrate how the compounds of the formula I can be incorporated in pharmaceutical compositions:
A syrup containing 2% (weight per volume) of active substance was prepared from the following ingredients:
______________________________________2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylthio]- 2.0 g(5-acetyl-6-methyl)benzimidazole.HClSaccharin 0.6 gSugar 30.0 gGlycerin 5.0 gFlavouring agent 0.1 gEthanol 96% 10.0 mlDistilled water (sufficient to obtain a finalvolume of 100 ml)______________________________________
Sugar, saccharin and the acid addition salt were dissolved in 60 g of warm water. After cooling, glycerin and a solution of flavouring agents dissolved in ethanol were added. To the mixture water was added to obtain a final volume of 100 ml.
The above given active substance may be replaced with other pharmaceutically acceptable acid addition salts.
2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylthio]-(5-methoxy)benzimidazole.HCl (250 g) was mixed with lactose (175.8 g), potato starch (169.7 g) and colloidal silicic acid (32 g). The mixture was moistened with 10% solution of gelatin and was ground through a 12-mesh sieve. After drying, potato starch (160 g), talc (50 g) and magnesium stearate (5 g) were added and the mixture thus obtained was pressed into tablets (10.000), with each tablet containing 25 mg of active substance. Tablets can be prepared that contain any desired amount of the active ingredient.
Granules were prepared from 2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylthio]-(5-carbomethoxy-6-methyl)benzimidazole base (250 g), lactose (175.9 g) and an alcoholic solution of polyvinylpyrrolidone (25 g). After drying, the granules were mixed with talc (25 g), potato starch (40 g), and magnesium stearate (2.50 g) and were pressed into 10.000 tablets. These tables are first coated with a 10% alcoholic solution of shellac and thereupon with an aqueous solution containing saccharose (45%), gum arabic (5%), gelatin (4%), and dyestuff (0.2%). Talc and powdered sugar were used for powdering after the first five coatings. The coating was then covered with a 66% sugar syrup and polished with a solution of 10% carnauba wax in carbon tetrachloride.
2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylthio]-(5-acetyl-6-methyl)benzimidazole hydrochloride (1 g), sodium chloride (0.6 g) and ascorbic acid (0.1 g) were dissolved in sufficient amount of distilled water to give 100 ml of solution. This solution, which contains 10 mg of active substance for each ml, was used in filling ampoules, which were sterilized by heating at 120° C. for 20 minutes.
Chronic gastric fistula dogs (Heidenhain pouch dogs) were used. These dogs have been surgically provided with a gastric cannula in the pouch. Following a 4 weeks' recovery period after surgery, tests were performed once a week on each dog. Food and water were withdrawn 18 hours before each test.
Gastric acid secretion was induced by continuous infusion of histamine at individual doses (100-300 μmol/kg, h), resulting in submaximal secretion of gastric acid. At least 2 hours after onset of stimulation, when the gastric acid secertion had reached a steady level, the test compounds in the form of free base suspended in 0.5% Methocel® (90 HG, 15.000, Dow Chem. corp.), were given orally by stomach tube. The gastric juice was collected by free flow from the gastric cannula in consecutive 30 minutes samples for 3 hours. The samples were titrated to pH 7.0 with 0.1M NaOH using a Radio-meter automatic titrator and the acid output was calculated.
The percent inhibition of acid secretion was calculated by comparing in each dog the acid output in the tests to the acid output in control tests when only the vehicle was given.
The test results are given in Table 6 below.
TABLE 6______________________________________Gastric acid secretion inhibiting effect on conscious dogsTest compound ##STR19## (μmol/Dose inhi-(%EffectR.sup.1 R.sup.2 R R.sup.3 R.sup.4 R.sup.5 kg) bition)______________________________________5-OCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.3 2 755-COOCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.3 8 505-COOCH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 CH.sub.3 2 805-COCH.sub.3 6-CH.sub.3 H CH.sub.3 OCH.sub.3 CH.sub.3 2 355-COCH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.3 8 905-CH.sub.3 H H CH.sub.3 OCH.sub.3 CH.sub.3 2 605-COCH.sub.3 6-CH.sub.3 H H CH.sub.3 CH.sub.3 8 805-OCH.sub.3 H H CH.sub.3 CH.sub.3 CH.sub.3 2 75______________________________________
It is seen in Table 6 that the tested compounds after oral administration exhibited a high inhibiting effect on the gastric secretion.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4045563 *||11 Nov 1975||30 Aug 1977||Ab Hassle||Substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid secretion inhibiting effects|
|US4045664 *||31 Aug 1972||30 Aug 1977||U.S. Philips Corporation||Lighting fitting provided with at least two-low-pressure mercury vapor discharge lamps|
|US4182766 *||11 Sep 1978||8 Jan 1980||Hoffmann-La Roche Inc.||Naphth[2,3-d]imidazoles|
|US4255431 *||5 Apr 1979||10 Mar 1981||Aktiebolaget Hassle||Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion|
|US4337257 *||19 May 1980||29 Jun 1982||Aktiebolaget Hassle||Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion|
|US4359465 *||28 Jul 1980||16 Nov 1982||The Upjohn Company||Methods for treating gastrointestinal inflammation|
|BE890024A1 *||Title not available|
|EP0005129B1 *||3 Apr 1979||29 Apr 1981||Aktiebolaget Hässle||Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation|
|EP0045200A1 *||24 Jul 1981||3 Feb 1982||The Upjohn Company||Benzimidazoles and their pharmaceutical use|
|GB1500043A *||Title not available|
|GB1525958A *||Title not available|
|1||*||Aktiebolag Hassle, Chem. Abst. 88:105333f.|
|2||*||Berntsson et al. Chem. Abst. 96:68986p, 91:193309t, 91:157736w.|
|3||*||Varga et al., Chem. Abst. vol. 83, 201872y.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5223515 *||4 Aug 1992||29 Jun 1993||Takeda Chemical Industries, Ltd.||Injectable solution containing a pyridyl methylsulfinylbenzimidazole|
|US5504082 *||1 Dec 1994||2 Apr 1996||Yoshitomi Pharmaceutical Industries, Ltd.||Pyridine compound and pharmaceutical compostions|
|US5616581 *||2 Jun 1995||1 Apr 1997||Yoshitomi Pharmaceutical Industries, Ltd.||Pharmaceutical use of pyridine compounds|
|US5708013 *||21 Aug 1995||13 Jan 1998||Eisai Co., Ltd.||Pyridine derivative and therapeutic agent for ulcer comprising the same|
|US6245913||30 Jun 1999||12 Jun 2001||Wockhardt Europe Limited||Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole|
|US6376666||11 May 1995||23 Apr 2002||Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk||2-mercaptobenzimidazole derivatives possessing pharmacological activity|
|US8722026||4 Jan 2011||13 May 2014||Elc Management, Llc||Skin lightening compositions|
|US8992897 *||19 Oct 2012||31 Mar 2015||Elc Management Llc||Skin lightening compositions|
|US9314415||26 Sep 2013||19 Apr 2016||Elc Management Llc||Skin lightening compositions|
|US20110171149 *||4 Jan 2011||14 Jul 2011||Yoko Niki||Skin Lightening Compositions|
|US20140212365 *||19 Oct 2012||31 Jul 2014||Yoko Niki||Skin lightening compositions|
|WO1995034304A1 *||11 May 1995||21 Dec 1995||Nauchno-Issledovatelsky Institut Farmakologii Rossiyskoi Akademii Meditsinskikh Nauk||Pharmacologically active 2-mercaptobenzimidazole derivatives|
|U.S. Classification||514/338, 546/273.7|
|International Classification||A61K31/415, C07D401/12, A61P1/04, A61K31/4427, A61K31/44|
|2 Apr 1987||AS||Assignment|
Owner name: AKTIEBOLAGET HASSLE,SWEDEN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARLSSON, ENAR I.;LARSSON, HAKAN S.;VON WITTKEN SUNDELL,GUNHILD W.;AND OTHERS;SIGNING DATES FROM 19870302 TO 19870318;REEL/FRAME:004688/0793
Owner name: AKTIEBOLAGET HASSLE, S-431 83 MOLNDAL, SWEDEN, A C
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:CARLSSON, ENAR I.;LARSSON, HAKAN S.;VON WITTKEN SUNDELL, GUNHILD W.;AND OTHERS;REEL/FRAME:004688/0793;SIGNING DATES FROM 19870302 TO 19870318
|8 Nov 1988||CC||Certificate of correction|
|30 Sep 1991||FPAY||Fee payment|
Year of fee payment: 4
|26 Sep 1995||FPAY||Fee payment|
Year of fee payment: 8
|14 Dec 1999||REMI||Maintenance fee reminder mailed|
|21 May 2000||LAPS||Lapse for failure to pay maintenance fees|
|1 Aug 2000||FP||Expired due to failure to pay maintenance fee|
Effective date: 20000524